Sonexa Therapeutics (San Diego, CA) a development stage company focused Alzheimer’s closed a $30M Series A financing. Participants include Domain Associates, Scale Venture Partners, Alta Partners, AgeChem Venture Fund and MC Life Science Ventures.

NGM Biopharmaceuticals (Hillsborough, CA) an early-stage drug development company focused on metabolic diseases closed a $25.5M Series A financing. Participants include Column Group, Prospect Venture Partners and Rho Ventures.

Point Biomedical (San Carlos, CA) a myocardial perfusion imaging platform has closed a $50M Series A recapitalization financing. Participants include Vedanta Capital, Amberbrook, Fininvest, INVESCO Private Capital, New Leaf Venture Partners, Saratoga Ventures, William Blair Capital Partners, De Novo Ventures, Institutional Venture Partners, Saints Capital, Sprout Group and CHL Medical Partners.

Sonexa Therapeutics (San Diego, CA) a development stage biopharmaceutical company focused on the treatment of Alzheimer’s disease closed a $30M Series A financing. Participants include Domain Associates, Scale Venture Partners, Alta Partners, AgeChem Venture Fund and MC Life Science Ventures.

Follica (Boston, MA) is developing novel therapies for the treatment of androgenetic alopecia and other disorders associated with the hair follicle has, closed a $5.5M Series A financing. Participants include Interwest Partners and PureTech Ventures.

Arcion Therapeutics (Baltimore, MD) a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain treatment in diabetic neuropathy and post-herpetic neuralgia closed a $8.8M Series A financing. Participants include CMEA Ventures and InterWest Partners.

Vivendy Therapeutics (Switzerland) developer of an enzyme replacement therapy for morbus morquio, a rare lysosomal storage disease closed a $15.5M Series A financing. Participants include BioMedInvest, LSP Life Sciences Partners and TVM Capital.

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

CyberHeart (Menlo Park, CA) a medical device company developing the first totally non-invasive system to treat cardiac arrhythmias closed a $9M Series A financing. Participants include Emergent Medical Ventures, and United Investments, Venture Select and Mitsubishi Corporation.

Benvenue Medical (Mountain View, CA) developer of minimally invasive devices for spine surgery closed a $15M Series B financing. Participants include Three Arch Partners, Versant Ventures and De Novo Ventures.